Prevnar 20

Pfizer wins FDA nod for Prevnar 20 pneumonia vaccine in children
Pfizer wins FDA nod for Prevnar 20 pneumonia vaccine in children
Seeking Alpha
Pfizer
vaccines
FDA
Prevnar 20
pneumococcal disease
pediatric
Flag link:
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
Endpoints
FDA
priority review
Pfizer
Prevnar 20
vaccines
Roche
bispecific antibodies
glofitamab
lymphoma
Flag link:
After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win
After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win
Endpoints
Vaxcyte
vaccines
VAX-24
pneumococcal disease
Pfizer
Prevnar 20
clinical trials
Flag link:
Pfizer's 20-valent pneumococcal vaccine hits goal in infant trial, teeing up 2022 approval filing
Pfizer's 20-valent pneumococcal vaccine hits goal in infant trial, teeing up 2022 approval filing
Fierce Biotech
Pfizer
vaccines
Prevnar 20
FDA
infants
clinical trials
pneumococcal disease
Flag link:
Pfizer, Merck next-gen pneumococcal vaccines score key CDC panel's backing on way to rival rollouts
Pfizer, Merck next-gen pneumococcal vaccines score key CDC panel's backing on way to rival rollouts
Fierce Pharma
Pfizer
Merck
pneumococcal disease
vaccines
Prevnar 20
Vaxneuvance
CDC
Flag link:
Pfizer's next-gen Prevnar 20 can be administered with a flu shot, study finds
Pfizer's next-gen Prevnar 20 can be administered with a flu shot, study finds
Fierce Pharma
Pfizer
Prevnar 20
vaccines
flu vaccines
COVID-19
Flag link:
Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
Motley Fool
Merck
Pfizer
vaccines
Vaxneuvance
Prevnar 20
pneumococcal disease
Flag link:
Pfizer rolls out next-gen pneumococcal vaccine with FDA win, beating Merck's 15-valent candidate to the punch
Pfizer rolls out next-gen pneumococcal vaccine with FDA win, beating Merck's 15-valent candidate to the punch
Endpoints
Pfizer
FDA
Merck
pneumococcal disease
vaccines
Prevnar 20
Flag link: